Hanall Biopharma (A009420) Stock Overview
A pharmaceutical company, manufactures and sells pharmaceutical products in South Korea and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
A009420 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Hanall Biopharma Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩54,100.00 |
| 52 Week High | ₩73,000.00 |
| 52 Week Low | ₩27,050.00 |
| Beta | 0.88 |
| 1 Month Change | -5.75% |
| 3 Month Change | 17.35% |
| 1 Year Change | 94.96% |
| 3 Year Change | 123.09% |
| 5 Year Change | 123.55% |
| Change since IPO | 5,310.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| A009420 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 24.7% | 10.3% | -4.2% |
| 1Y | 95.0% | -8.0% | 84.8% |
Return vs Industry: A009420 exceeded the KR Pharmaceuticals industry which returned -8% over the past year.
Return vs Market: A009420 exceeded the KR Market which returned 84.8% over the past year.
Price Volatility
| A009420 volatility | |
|---|---|
| A009420 Average Weekly Movement | 18.0% |
| Pharmaceuticals Industry Average Movement | 7.2% |
| Market Average Movement | 9.9% |
| 10% most volatile stocks in KR Market | 17.8% |
| 10% least volatile stocks in KR Market | 5.2% |
Stable Share Price: A009420's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A009420's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1973 | 304 | Seung-Kook Park | www.hanall.co.kr |
Hanall Biopharma Co., Ltd., a pharmaceutical company, manufactures and sells pharmaceutical products in South Korea and internationally. The company offers prescription drugs and over-the-counter products for the treatment of diarrhea, prostatic hyperplasia, androgenetic alopecia, chronic renal failure, hypoparathyroidism, vitamin D-resistant rickets, osteomalacia, osteoporosis, prostate cancer, toxic liver disease, chronic hepatitis, liver cirrhosis, male pattern baldness, functional dyspepsia, diabetes, bacterial infections, peripheral vascular disorders, hypertension, chronic heart failure, skin diseases, hypoproteinemia, diabetic polyneuritis, ulcers, high blood pressure, arthritis, endocrine disorders, spasms, insomnia, muscle pain, hypoproteinemia, gastroesophageal reflux disease, allergic rhinitis, conjunctivitis, dermatitis, chronic urticaria, cholesterol cholelithiasis, gastritis, neurological diseases, erectile dysfunction, hyperphosphatemia, urinary tract infection, spastic paralysis, fungal infections, dysmenorrhea, hypercholesterolemia, constipation, abdominal distension, abdominal fermentation in the intestines, neuralgia, capillary weakness, post-phlebitis syndrome, irritable bowel syndrome, spastic colon, and hemorrhoids, as well as vitamin D, vitamin B1, vitamin B12, and calcium deficiency. It develops products in the fields of ophthalmology, immunology, oncology, and neurology, such as HL192 for Parkinson’s disease; HL036 for dry eye disease; HL161 for myasthenia gravis, thyroid eye disease, warm autoimmune hemolytic anemia, neuromyelitis optica, immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy, and graves’ disease; and HL187 and HL186 for immuno-oncology.
Hanall Biopharma Co., Ltd. Fundamentals Summary
| A009420 fundamental statistics | |
|---|---|
| Market cap | ₩2.75t |
| Earnings (TTM) | -₩5.08b |
| Revenue (TTM) | ₩159.06b |
Is A009420 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A009420 income statement (TTM) | |
|---|---|
| Revenue | ₩159.06b |
| Cost of Revenue | ₩76.17b |
| Gross Profit | ₩82.89b |
| Other Expenses | ₩87.97b |
| Earnings | -₩5.08b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -99.95 |
| Gross Margin | 52.11% |
| Net Profit Margin | -3.19% |
| Debt/Equity Ratio | 26.6% |
How did A009420 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/09 10:19 |
| End of Day Share Price | 2026/08/07 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hanall Biopharma Co., Ltd. is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ka-hye Hong | Daishin Securities Co. Ltd. |
| Jonghyun Park | DAOL Investment & Securities Co., Ltd. |
| null null | DBS Bank Ltd |